Syndivia is a biotechnology company dedicated to developing a new generation of targeted drugs for the treatment of cancer.

It develops innovative bioconjugation technologies to link biological objects with functional molecules. 

The spectrum of application of these technologies ranges from the development of new reagents for research to the implementation of novel targeted cancer therapies.

Syndivia's technology platform provides a stable and controllable way to conjugate potent cytotoxics with monoclonal antibodies, thereby increasing the therapeutic index of anti-cancer drugs